The short version: while semaglutide and tirzepatide sat on FDA's drug shortage list, federal compounding law let pharmacies legally prepare versions of them — and a multibillion-dollar compounded-GLP industry grew inside that window.
Compounding is a licensed pharmacy preparing a drug itself, mixing or altering ingredients to fill a prescription, rather than dispensing a manufacturer's finished product; a compounder is the pharmacy or facility that does it.
FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, and the wind-down periods that followed closed the main legal basis for compounded copies by spring 2025.
Since then the pressure has moved to three fronts: an extensive litigation campaign by the brand manufacturers, FDA Import Alert 66-80 putting GLP-1 bulk imports under detention-by-default as of September 2025, and state pharmacy boards.
Research-use-only vendors sit outside the compounding fight entirely — selling compounds labeled not for human consumption — and the enforcement letters that do land in that market typically target human-use claims, not the molecules alone.
- The compounded-GLP market was a creature of the shortage list. The legal basis for copying a brand drug exists only while that drug is officially in shortage. That is a switch FDA controls, and FDA turned it off.
- The window closed on paper in spring 2025. Tirzepatide's shortage was declared resolved in late 2024, semaglutide's in early 2025, each followed by staged wind-down deadlines for different classes of compounder.
- Enforcement now runs through three channels — brand-manufacturer litigation, import detention under Import Alert 66-80, and state pharmacy boards. Each moves at a different speed against a different target.
- The research-peptide market is adjacent to this fight, not inside it. RUO [research use only] vendors sell chemicals not for human consumption; the FDA letters that reach this market typically cite human-use claims paired with the molecules, not mere possession of a sequence.
- The next structural shock is an approval, not a ban. A retatrutide approval would redraw the map the way semaglutide's shortage resolution did — watch the evidence file, because the regulatory clock runs on it.
Built by a rule
Federal law lets pharmacies compound a copy of an approved drug while it sits on FDA’s shortage list. Semaglutide and tirzepatide sat there for years, and an industry grew in the gap.
Here is the part of the GLP-1 story that rarely survives the retelling: the compounded semaglutide boom was not an evasion of federal drug law. It was an application of it.
Sections 503A and 503B of the Food, Drug, and Cosmetic Act are the framework governing pharmacy compounding. They generally prohibit compounders from producing what amounts to a copy of a commercially available, FDA-approved drug. Section 503A covers state-licensed pharmacies compounding for an identified patient against a prescription.
Section 503B covers outsourcing facilities — compounders that register with FDA and may prepare batches without a patient-specific prescription, under tighter manufacturing requirements.
But the framework carves out an exception with enormous consequences. When a drug appears on FDA's official drug shortage list, the copying restriction relaxes. Compounders may then prepare versions of it to cover the gap the manufacturer cannot fill.
Semaglutide and tirzepatide both entered the shortage database as demand for the branded products outran manufacturing. From that moment, a licensed compounding pharmacy preparing semaglutide was doing something the statute contemplated.
Telehealth platforms wired prescribing to compounding at national scale. Hims & Hers, most visibly, moved into compounded semaglutide during the shortage era and said so publicly. An industry that had never existed reached large numbers of patients in roughly two years.
The whole edifice rested on one premise: the word shortage next to two entries in an FDA database.
The unwind, on the record
FDA declared both shortages resolved and the staged wind-down deadlines ran out in spring 2025. The legal basis for compounded copies closed with them.
Rules that create markets can dissolve them, and this one did it on a schedule you can read in the shortage database itself. FDA declared the tirzepatide shortage resolved in late 2024. The semaglutide resolution followed in early 2025.
Each declaration started a wind-down clock. The staged deadlines differed for state-licensed 503A pharmacies and 503B outsourcing facilities. By spring 2025 the last of those grace periods had expired.
After that, preparing what is essentially a copy of the approved products lost the legal basis the entire industry had been standing on.
| when | what happened | what it changed |
|---|---|---|
| 2022 | Semaglutide and tirzepatide enter FDA's drug shortage database. | The copying restriction relaxes — compounded versions gain a legal basis. |
| 2022–2024 | Telehealth-plus-compounding platforms scale nationally. | Compounded GLP-1s reach mainstream patients at a fraction of brand price. |
| late 2024 | FDA declares the tirzepatide shortage resolved. | First wind-down clock starts; compounders and trade groups contest the call. |
| early 2025 | FDA declares the semaglutide shortage resolved. | The larger market gets its own wind-down deadlines. |
| spring 2025 | Staged wind-down periods expire for 503A and 503B compounders. | The main legal window for compounded copies closes. |
| sep 2025 | FDA issues Import Alert 66-80 for GLP-1 bulk drug substances. | Detention without physical examination — border enforcement by default. |
| 2026 | Litigation, state-board actions, and import enforcement grind on. | The market fragments into on-label, repositioned, and gray channels. |
Repositioning, not retreat
The industry did not fold. It moved to personalised doses, uncopied molecules and contested legal theories, with Lilly and Novo Nordisk litigating behind it.
An industry that large does not simply file itself away, and 2025 and 2026 have been a study in repositioning.
Some compounding and telehealth players moved toward offerings they argue sit outside the copying prohibition. Personalized doses, altered formulations, different delivery formats. It is a legal theory that is actively contested, and we will not flatter it with more confidence than it has earned.
Others shifted to molecules with no approved competitor to copy. Others exited. The common thread is that everyone in the space is now navigating around the statute rather than through the doorway it once held open.
Against all of it runs the money. The brand manufacturers, Lilly and Novo Nordisk, have pursued an extensive litigation campaign against compounders, telehealth sellers, and med spas trading on their molecules.
We will not recite case names or outcomes here — the docket moves faster than any article. But the strategic shape is stable and worth stating plainly.
This is a turf war over who may sell two of the most commercially valuable molecules in pharmaceutical history. It is fought with shortage determinations, complaints, and import paperwork rather than press releases. Calling it a safety story or a greed story flattens it. It is an inventory story with three armies.
The border becomes the chokepoint
Detaining bulk powder stops everything downstream at once. That is why import policy now does more work than any single lawsuit.
The most structurally important move of the period was not a lawsuit. In September 2025, FDA issued Import Alert 66-80, placing GLP-1 bulk drug substances under detention without physical examination.
Translated from customs language, shipments of the raw powder can now be held at the border by default. The burden sits on the importer to demonstrate admissibility, rather than on the agency to inspect and object shipment by shipment.
That flipped the enforcement geometry. Suing sellers is retail work — one defendant at a time. Detaining powder is wholesale — everything downstream of the border starves at once, whatever the seller's paperwork says.
Since nearly all peptide raw material is synthesized overseas, the alert reaches compounders and research-chemical suppliers alike through the one artery they share.
We traced that artery — who synthesizes, how material moves, and what detention-by-default has done to it — in our supply-chain report. It is the necessary companion to this article.
Where research-use-only sits
Research-use-only vendors were never inside the shortage window, so its closure did not move them. What draws a warning letter is the marketing, not the molecule.
Now to the question this site's readers care about most, answered without the wishful thinking that infects most vendor copy. Research-use-only vendors are not compounders.
They do not hold pharmacy licenses, do not fill prescriptions, and were never operating inside the shortage window. So its closure did not, by itself, change their legal posture.
What they sell is a chemical labeled for laboratory research, explicitly not for human consumption. That category exists legitimately, because research on these molecules is real and ongoing.
But the lane is narrow, and its boundary is drawn by claims rather than chemistry. An FDA warning letter is the agency's written notice that it considers a firm to be in significant violation. The letter names the conduct and demands correction within a stated period.
It is not a court order, not a fine, and not a finding of guilt — enforcement action, where it follows, comes after.
Survey the warning letters that actually land in this market and a consistent pattern emerges. The agency's attention concentrates where the label says research while the marketing says otherwise. Human dosing guidance, weight-loss framing, testimonials, disease claims paired with the molecules.
A vendor selling a vial with a certificate and no human-use language is one enforcement target. A vendor selling the same vial next to a dosing calculator is a categorically different one.
That is also why the honest consumer-protection layer in this market is documentary, not regulatory. Nobody inspects these products on your behalf. That is exactly why reading a certificate of analysis is a survival skill rather than a hobby.
None of this makes the RUO market safe, in either the legal or the chemical sense. It makes it legible. The rules that govern it are knowable, the enforcement pattern is observable, and both point the same direction. Claims draw fire, and the border is the chokepoint.
What to watch
Three things decide 2027: state pharmacy boards, how widely Import Alert 66-80 is actually enforced, and whether retatrutide is approved.
State pharmacy boards. The federal window closed, but pharmacy practice is licensed state by state, and boards move at their own pace against compounders testing the personalized-dose theory. State actions are less visible than federal ones and, for an individual pharmacy, more existential.
Import enforcement in practice. An import alert is a policy. Detentions are a practice. Watch how broadly 66-80 gets applied, whether adjacent non-GLP molecules start seeing similar treatment, and how supply routes adapt. The pattern in shipping workarounds will tell you more about 2027 than any press statement.
A retatrutide approval. The next structural shock will likely be an approval rather than a ban.
Retatrutide is the most-watched molecule in the pipeline, and an approval would redraw the map twice over. It creates an on-label route for the demand currently pooling in the gray market. It also converts every unapproved seller of the molecule into a competitor of a marketed product, historically the moment enforcement interest sharpens.
The clinical record that approval would rest on is laid out in our retatrutide evidence file.
The through-line of the whole story: this market was never governed by whether the molecules work. It is governed by lists. The shortage list, the import alert list, the litigation docket. The entries on those lists change by administrative act, sometimes overnight.
Anyone operating in or buying from this market in 2026 is holding a position on what those lists will say next. Whether they know it or not.
FAQ
Why was compounded semaglutide ever legal?
Because of the shortage mechanism in federal compounding law. Sections 503A and 503B of the Food, Drug, and Cosmetic Act set the rule. They generally prohibit compounders from producing what amounts to a copy of a commercially available, FDA-approved drug.
That restriction relaxes when the drug appears on FDA's official shortage list. Pharmacies may then prepare versions of it to cover the gap the manufacturer cannot fill. Semaglutide and tirzepatide both entered the shortage database as demand for the branded products outran manufacturing.
Tirzepatide spent about two years on the list and semaglutide closer to three. From the moment they were listed, a licensed compounding pharmacy preparing semaglutide was doing something the statute contemplated. The boom was an application of federal drug law, not an evasion of it.
Telehealth platforms then wired prescribing to compounding at national scale. An industry that had never existed reached large numbers of patients in roughly two years.
When did the compounded GLP-1 window close?
On a schedule you can read in the shortage database itself. FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025.
Each declaration started a wind-down clock, with staged deadlines that differed for state-licensed 503A pharmacies and 503B outsourcing facilities. By spring 2025 the last of those grace periods had expired.
After that, preparing what is essentially a copy of the approved products lost the legal basis the entire industry had been standing on. Compounders and trade groups contested the tirzepatide call as the first clock started. The industry did not fold.
Some players moved toward personalized doses, altered formulations, and different delivery formats they argue sit outside the copying prohibition. That theory is actively contested. Others shifted to molecules with no approved competitor to copy. Others exited.
Are research-use-only vendors legal?
They occupy a narrow lane, not a safe harbor. RUO vendors are not compounders. They hold no pharmacy licenses, do not fill prescriptions, and were never operating inside the shortage window. So its closure did not by itself change their legal posture.
What they sell is a chemical labeled for laboratory research and explicitly not for human consumption. That category exists legitimately, because research on these molecules is real and ongoing.
The boundary of the lane is drawn by claims rather than chemistry. The warning letters that land in this market concentrate where the label says research while the marketing says otherwise. Human dosing guidance, weight-loss framing, testimonials, disease claims paired with the molecules.
A vendor selling a vial with a certificate and no human-use language is one enforcement target. A vendor selling the same vial next to a dosing calculator is a categorically different one.
What did Import Alert 66-80 change?
It moved enforcement upstream, from sellers to supply. In September 2025 FDA issued Import Alert 66-80, placing GLP-1 bulk drug substances under detention without physical examination.
Translated from customs language, shipments of the raw powder can be held at the border by default. The burden sits on the importer to demonstrate admissibility, rather than on the agency to inspect and object shipment by shipment. That flipped the enforcement geometry.
Suing sellers is retail work — one defendant at a time. Detaining powder is wholesale — everything downstream of the border starves at once, whatever the seller's paperwork says.
Because nearly all peptide raw material is synthesized overseas, the alert reaches compounders and research-chemical suppliers alike through the one artery they share. An import alert is a policy and detentions are a practice, so what matters next is how broadly it gets applied.
Would a retatrutide approval end the gray market for it?
It would reshape it rather than end it. Retatrutide is the most-watched molecule in the pipeline, and an approval would redraw the map twice over. It creates an on-label route for the demand currently pooling in the gray market.
It also converts every unapproved seller of the molecule into a competitor of a marketed product — historically the moment enforcement interest sharpens.
What decides how much demand actually migrates is not the approval itself but access: pricing, insurance coverage, and prescribing friction. The semaglutide history is the guide, and it suggests gray demand shrinks where the legal product is reachable and persists where it is not.
Note the direction of travel too — the next structural shock in this market will likely be an approval rather than a ban. The clinical record it would rest on is in our retatrutide evidence file.
References
- FDA Drug Shortage Database — the primary record for shortage listings and resolutions — accessdata.fda.gov
- FDA, Human Drug Compounding — the agency's hub for 503A/503B policy — fda.gov
- FDA, Drug Shortages overview and policy pages — fda.gov
- FDA Import Alert 66-80, Detention Without Physical Examination of GLP-1 Bulk Drug Substances — accessdata.fda.gov
- Inside Your Peptides, Where Peptide Powder Comes From — the supply-chain report behind the import-enforcement story
- Inside Your Peptides, The Retatrutide Evidence File — the clinical record a future approval would rest on
disclosure: inside your peptides is published by the owners of the next lab, the only vendor we are paid by, including the next lab. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.